Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Xinyi
X
Yang
Arkansas Skin Cancer Center, Little Rock.
Scott M
SM
Dinehart
D000328:Adult; D000813:Anilides / Q000008:administration & dosage* / Q000009:adverse effects / Q000819:agonists; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001478:Basal Cell Nevus Syndrome / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects / Q000819:agonists; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
D000813:Anilides; D000970:Antineoplastic Agents; C538724:HhAntag691; D011725:Pyridines